hVIVO plc
("hVIVO", the "Company" or
the "Group")
Proposed Cancellation of
Admission to Trading on Euronext Growth
hVIVO plc (AIM & Euronext: HVO),
a fast-growing specialist contract research organisation (CRO) and
world leader in testing infectious and respiratory disease products
using human challenge clinical trials, announces its intention to
cancel its admission ("the Cancellation") to trading on Euronext
Growth.
As hVIVO's primary operations, along
with the majority of its employees and investor base, are in the
UK, the Board has decided to consolidate
trading of the Company's stock to its primary listing on the AIM
Market of the London Stock Exchange. The Cancellation will also
remove certain costs, complexities and duplication that comes from
administering two listing regimes and will have no impact on
hVIVO's Ordinary Shares which will continue to trade on AIM under
the ticker "HVO".
In accordance with the Euronext
Growth Rules, the Company has notified Euronext of the proposed
Cancellation. Under the Euronext Growth Rules, the Cancellation can
only take place after the expiry of a minimum period of twenty
Business Days from the date on which notice of the Cancellation is
given. Accordingly, it is intended that the Cancellation will
become effective at 7.00 a.m. on 2 September 2024.
For
further information please contact:
|
hVIVO plc
|
+44 (0) 20
7756 1300
|
|
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
|
+44 (0) 20
7220 0500
|
|
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward
|
|
|
|
|
|
Peel Hunt LLP (Joint Broker)
|
+44 (0)20
7418 8900
|
|
James Steel, Dr Christopher Golden
|
|
|
|
|
|
Davy (Euronext Growth Adviser and Joint
Broker)
|
+353 (0) 1
679 6363
|
|
Anthony Farrell, Niall
Gilchrist
|
|
|
|
|
|
Walbrook PR (Financial PR & IR)
Stephanie Cuthbert / Phillip
Marriage /
Louis Ashe-Jepson
|
+44 (0) 20
7933 8780 or hvivo@walbrookpr.com
+44 (0)
7796 794 663 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393
|
|
|
|
|
| |
Notes to
Editors
About
hVIVO
hVIVO plc
(ticker: HVO) is a fast-growing specialist contract research
organisation (CRO) and the world leader in testing infectious and
respiratory disease vaccines and therapeutics using human challenge
clinical trials. The Group provides end-to-end early clinical
development services to its large, established and growing repeat
client base, which includes four of the top 10 largest global
biopharma companies.
The Group's fast-growing services business
includes a unique portfolio of 11 human challenge models, with a
number of new models under development, to test a broad range of
infectious and respiratory disease products. The Group has world
class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life
Sciences brand, and a lab offering via its hLAB brand, which
includes virology, immunology biomarker and molecular testing. The
Group also offers additional clinical field trial services such as
patient recruitment and clinical trial site services.
hVIVO runs challenge trials in London -
its new state-of-the-art facilities in Canary Wharf opened in 2024
and is the world's largest commercial human challenge trial unit,
with highly specialised on-site virology and immunology
laboratories, and an outpatient unit. To recruit volunteers /
patients for its studies, the Group leverages its unique clinical
trial recruitment capability via its FluCamp volunteer screening
facilities in London and Manchester.